Glenn Boehnlein, Kevin King and Mary Kay Ladone
Appointed as Independent Directors
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the appointment of Glenn Boehnlein, Kevin
King, and Mary Katherine Ladone to Inogen’s Board of Directors,
effective March 22, 2022. In conjunction with these appointments,
Heath Lukatch (director since 2006), Benjamin Anderson-Ray
(director since 2013), and Loren McFarland (director since 2013)
retired from the Board.
Elizabeth Mora, Chairperson of the Board, said: “Maintaining a
Board with diverse, fresh perspectives, skills, and experience to
drive shareholder value is of utmost priority for Inogen and we are
thrilled to welcome Glenn, Kevin, and Mary Kay to the Inogen Board.
Each of them brings unique experiences and an extensive track
record of helping guide and grow successful MedTech companies,
which we believe positions them to support our overarching goal of
transforming Inogen into a prominent leader in respiratory
care.”
Ms. Mora continued, “Under the leadership of Nabil Shabshab,
Inogen’s President and CEO, and his executive leadership team of
industry veterans, we have continued to successfully execute on our
strategic initiatives, including advancing our prescriber growth
strategy and driving productivity and efficiency of our commercial
operations. The addition of Glenn, Kevin and Mary Kay will further
elevate the partnership between the Board and the executive team to
advance Inogen’s transformation into a global respiratory care
leader with durable and sustainable top-line growth and a path to
bottom-line growth. On behalf of the entire Board and the executive
leadership team, we welcome Glenn, Kevin and Mary Kay and look
forward to working with them.”
Ms. Mora continued, “Heath, Ben and Loren’s partnership, input
and guidance have been invaluable over their years of service to
Inogen. I want to thank each of them for their commitment and for
their many valuable contributions. Each of Heath, Ben, and Loren
joined the Board while Inogen was a private company, and their
tenure has notably included our initial public offering in 2014 and
the continued development of innovative oxygen therapy solutions
designed to improve the lives of patients worldwide.”
In connection with the appointment of the new Board members,
Inogen also reconstituted the committees of the Board. The
committee chairs will be Glenn Boehnlein for the Audit Committee,
Kevin King for the Compensation Committee, Heather Rider for the
Nominating & Governance Committee, and Elizabeth Mora for the
Compliance Committee. Inogen is maintaining the total number of
members on its Board of Directors at seven and the Director Classes
are Heather Rider and Elizabeth Mora in Class I, Nabil Shabshab,
Kevin King, Mary Kay Ladone in Class II, and Kristen Miranda and
Glenn Boehnlein in Class III.
Glenn Boehnlein Biography
Glenn S. Boehnlein currently serves as Vice President, Chief
Financial Officer at Stryker Corporation (NYSE: SYK). In this role,
Mr. Boehnlein is responsible for global finance activities which
include corporate accounting, reporting, tax, treasury, and
internal audit. Additionally, he is also responsible for global
information technology and investor relations.
In 2003, Mr. Boehnlein began his career at Stryker as Chief
Financial Officer for their Endoscopy division. Since then, he has
served in roles of increasing responsibility at Stryker, including
group CFO of MedSurg and Neurotechnology. Prior to joining Stryker,
Mr. Boehnlein spent three years with MyPrimeTime as CFO, and prior
to that, he was a partner and certified public accountant at Arthur
Andersen.
Mr. Boehnlein holds a bachelor’s and master’s degree in
accounting from Mississippi State University.
Kevin King Biography
Kevin King has over three decades of experience in the
healthcare and IT industries in leadership roles. Until 2021, Mr.
King served as Chief Executive Officer, President at iRhythm
Technologies, Inc. (NASDAQ: IRTC). He recently announced his
retirement from iRhythm’s Board of Directors.
Before joining iRhythm, Mr. King was President, Chief Executive
Officer and Director of Affymetrix, Inc. (now part of Thermo Fisher
Scientific), a previously publicly-traded technology innovator in
the field of genetic analysis, where he spent four years. Prior to
joining Affymetrix in 2007, Mr. King served as President and Chief
Executive Officer of Thomson Healthcare, an information services
business, which focused on a range of healthcare-related
businesses.
Mr. King also held a number of senior executive positions at GE
Healthcare and began his career in HP’s Medical Products Group.
Mr. King has a bachelor’s degree in Economics and Biology from
the University of Massachusetts and an M.B.A. from New Hampshire
College. He also serves on the Board of two venture backed
healthcare companies, Cleerly Health and Flosonics.
Mary Katherine Ladone Biography
Mary Katherine (Mary Kay) Ladone is an accomplished executive
with over 30 years of experience serving large global healthcare
companies. Until January 2022, Ms. Ladone served as Corporate
Officer and Senior Vice President, Corporate Development, Strategy
& Investor Relations at Hill-Rom Holdings, Inc., which is now a
subsidiary of Baxter International, Inc. (NYSE: BAX).
Previously, Ms. Ladone served as Senior Vice President and
Corporate Officer, Investor Relations of Baxalta, Inc., a global
biopharmaceutical company spun out from Baxter International in
2015. She began her career in Finance at Baxter International, and
went on to serve in multiple financial, operational and
communication roles of increasing responsibility at the company
including leading Baxter’s investor relations between 2004 and
2015.
Ms. Ladone has consistently been recognized by the investment
community as a top investor relations professional, including
numerous designations by Institutional Investor. She currently is a
member of the Board of Directors of Bioventus Inc. (NASDAQ: BVS), a
global leader in innovations for active healing.
Ms. Ladone received a Bachelor of Business Administration degree
(Finance & Business Economics) cum laude from the University of
Notre Dame.
About Inogen
We are a medical technology company offering innovative
respiratory products for use in the homecare setting. We primarily
develop, manufacture and market innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced changes to Inogen’s board of directors; statements
concerning or implying Inogen’s future financial performance;
statements regarding Inogen’s goals and potential, including the
potential for Inogen to achieve durable and sustainable growth at
both the top-line and bottom-line; statements regarding the
partnership between Inogen’s board of directors and management; the
ability of management and board of directors personnel to
contribute to the execution of Inogen’s strategic plans and goals;
and the ability of Inogen to become a prominent leader in
respiratory care. Any statements contained in this communication
that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible,” and similar expressions are intended to identify
forward-looking statements. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
but not limited to, risks related to its announced management and
organizational changes, and risks arising from the possibility that
Inogen will not realize anticipated future financial performance or
strategic goals. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Annual
Report on Form 10-K for the period ended December 31, 2021, and in
its other filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005359/en/
Investor and Media Contacts Bryan Locke, Mike DeGraff,
Gabriella Coffey ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Sep 2023 to Sep 2024